Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 5:53:38-51.
doi: 10.1016/j.jot.2025.05.004. eCollection 2025 Jul.

N6-methyladenosine and intervertebral disc degeneration: Advances in detection and pathological insights

Affiliations
Review

N6-methyladenosine and intervertebral disc degeneration: Advances in detection and pathological insights

Bin Liu et al. J Orthop Translat. .

Abstract

Intervertebral disc (IVD) degeneration (IDD) is a progressive condition characterized by the deterioration of the intervertebral discs, which serve as cushions between the vertebrae in the spinal column. This degeneration is often associated with aging and can be influenced by various factors, including genetics, mechanical stress, and lifestyle choices. N6-methyladenosine (m6A) modification has emerged as a critical post-transcriptional regulatory mechanism that influences various biological processes, including cellular differentiation, proliferation, and response to stress. Recent studies suggest that m6A modification play significant roles in the pathophysiology of IDD. The dysregulation of m6A methylation is linked to the altered expression of genes involved in inflammation, oxidative stress, extracellular matrix remodeling, regulated cell death including apoptosis, autophagy, pyroptosis and ferroptosis, all of which contribute to the IDD. In this review, we summarize the advanced detection technology of m6A and the roles of m6A in pathological process of IDD, to provide new insights into the molecular mechanisms underlying IDD and identify novel therapeutic targets for intervention.

The translational potential of this article: This work underscores the diagnostic and therapeutic potential of targeting m6A mechanism in IDD. Clinically, m6A regulators may serve as biomarkers for early IDD detection or progression monitoring. Therapeutically, small-molecule modulators of m6A writers/erasers or RNA-based strategies could restore ECM homeostasis, mitigate inflammation, and prevent IVD cell death. Furthermore, advanced m6A mapping technologies may enable personalized interventions by decoding patient-specific epitranscriptomic profiles. These insights bridge molecular mechanisms to clinical innovation, offering novel avenues for IDD treatment and regenerative therapies.

Keywords: Cellular metabolism; Extracellular matrix metabolism; Intervertebral disc degeneration; Oxidative stress; Regulated cell death; m6A modification.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interest.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
Schematic diagram of healthy IVD, degenerated IVD, and pathological microenvironment.
Fig. 2
Fig. 2
The composition and function mechanism of m6A methylation. m6A methylation, a highly conserved RNA modification mechanism, is dynamically regulated by three key protein groups: writers (including METTL3, METTL14, WTAP, ZC3H13, VIRMA, RBM15 and so on.) that catalyze methylation; erasers (FTO and ALKBH5) responsible for demethylation; readers (YTHDF1/2/3, YTHDC1/2, IGF2BP1/2/3) that recognize m6A marks and mediate downstream effects on RNA fate. This modification system orchestrates multiple RNA bioprocesses, including RNA splicing, transcript processing, translation efficiency modulation, and degradation control, through its dynamic and reversible regulatory network.
Fig. 3
Fig. 3
Schematic diagrams of the mechanism of m6A methylation detection based on antibody method. (A) m6A-seq/MeRIP-seq technology. (B) m6A-seq technology. (C) m6A-miCLIP-seq technology. (D) m6A-LAIC-seq technology.
Fig. 4
Fig. 4
Schematic diagrams of the mechanism of m6A methylation detection based on chemical method. (A) m6A-seal-seq technology. (B) m6A-SAC-seq technology. (C) m6A-Lable-seq technology. (D) m6A-GLORI-seq technology.
Fig. 5
Fig. 5
Schematic diagrams of the mechanism of m6A methylation detection based on enzymatic method. (A) m6A-MAZTER-seq technology. (B) m6A-REF-seq technology. (C) m6A-DART-seq technology.
Fig. 6
Fig. 6
Functions of m6A and IDD links on inflammation, oxidative stress, ECM metabolism, regulated cell death, cell senescence, and signal pathway. In different biological processes, various m6A methyltransferases or demethylases undergo changes, which subsequently affect downstream molecular alterations and ultimately influence the progression of IDD. (a) Functions of m6A and IDD links on inflammation. The characteristic of IDD is the elevated levels of inflammatory cytokines TNF-α, IL-6 and IL-1β secreted by IVD cells themselves. (b) Functions of m6A and IDD links on oxidative stress. (c) Functions of m6A and IDD links on ECM metabolism. (d) Functions of m6A and IDD links on regulated cell death. (e) Functions of m6A and IDD links on cell senescence. (f) Functions of m6A and IDD links on signal pathway. The red arrow indicates upregulation of molecular expression, while the green arrow indicates downregulation of molecular expression.

Similar articles

References

    1. Martin B.I., Deyo R.A., Mirza S.K., Turner J.A., Comstock B.A., Hollingworth W., et al. Expenditures and health status among adults with back and neck problems. JAMA, J Am Med Assoc. 2008;299(6):656–664. - PubMed
    1. Mohd I.I., Mokhtar S.A., Abbah S.A., Fauzi M.B., Devitt A., Pandit A. Intervertebral disc degeneration: biomaterials and tissue engineering strategies toward precision medicine. Adv Healthcare Mater. 2022;11(13) - PMC - PubMed
    1. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. - PMC - PubMed
    1. Jin Z., Wang D., Zhang H., Liang J., Feng X., Zhao J., et al. Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017. Ann Rheum Dis. 2020;79(8):1014–1022. - PubMed
    1. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222. - PMC - PubMed

LinkOut - more resources